201409 provaxs brochure - algemeen

PROVAXS Your partner for innovation in animal health

INNOVATION THROUGH PARTNERSHIP AND COLLABORATION

YOUR PARTNER FOR INNOVATION IN ANIMAL HEALTH

4

Discover 3 reasons why PROVAXS can become the preferred academic partner to support your innovation-projects in animal health.

AN ENTREPRENEURIAL THE EXPERTISE,

ORGANIZATION OF

KNOWLEDGE

SCIENTISTS AND

AND KNOW HOW

EXPERIENCED TECH

OF OUR SCIENTISTS

TRANSFER PROFESSIONALS

PROVAXS

ACCESS TO PROOF OF CONCEPT FUNDING

5

PROVAXS offers access to a network of laboratories at the University of Ghent with a focus on infectious diseases and immunity that unite their expertise for the development of innovative vaccines, targeted therapeutics, feed additives and diagnostics.

We offer in depth academic expertise and research capacity on selected animal pathogens and the interaction with their host.

A network of leading professors, each with in depth expertise in one of the following animal diseases:

BACTERIA

• Actinobacillus

• Escherichia coli (APEC)

pleuropneumoniae

• Campylobacter

• Chlamydia trachomatis

• Chlamydia psittaci

• Escherichia coli F4/K88

• Clostridium perfringens

• Escherichia coli F18

• ornithobacterium

• Mycoplasma

• inotracheale

hyopneumoniae

• Salmonella

• Salmonella

VIRUS

• PCV2 • PPRSV • SIV

PARASITE

• Ascaris suum

• Cooperia oncophora

• Tocoplasma gondii

• Fasciola hepatica

• Trichuris suis

• Ostertagia ostertagi

6

THE EXPERTISE, KNOWLEDGE AND KNOW HOW of our scientists

• Mycotoxins in vitro and

• Escherichia coli

in vivo (pigs and poultry)

• White spot syndrome virus

• Toxoplasma gondii • giardia duodenalis

7

8

8

ACADEMIC AND REGULATORY EXPERTISE • Know how of professors and academic scientists who perform breakthrough research in their field of expertise • Tailor-made study design and protocol • In depth data evaluation and interpretation of results by academic experts • Ready-to-use results and reports • Experience in vaccine development • Contribution to WAAVP and VICH guidelines • Member of EMA advisory board

VARIOUS CHALLENGE MODELS AND IN VITRO MODELS • Efficacy studies according to WAAVP and VICH guidelines (including early evaluation of efficacy, comparative studies and studies for registration purposes) • Use of highly characterised challenge strains in reliable and reproducible models • Classical infection and seeder-models • Pathogenesis and vaccination-challenge studies • Various in vitro models to quantify virus replication and/or determine cell tropism e.g. polarized nasal explants, macrophages/ monocytes, cardiomyocytes • in vitro: MIC, transwell insert model, cell invasion test,…

• in vitro/in vivo: intestinal loop model (pig), caecal loop model (chicken)

9

OUR FOCUS IS ON ANIMAL HEALTH BUT SOME TECHNOLOGIES AND KNOW HOW CAN BE USED FOR OR TRANSLATED TO APPLICATIONS IN HUMAN MEDICINE.

10

EXPERIENCED BSL2/3 LABORATORIES AND ANIMAL FACILITIES • Sample analysis in a broad diagnostic context (bacteriological, virological, parasitological ) • Quantification of pathogenic load upon infection and/or vaccinationchallenge (e.g. organs, excretions, blood) • Quantification of serological responses to vaccination and infection • Necropsy and histopathology • Genetic sequencing and analysis FIELD STUDIES • Networking with farmers and farm organisations • Efficacy studies under field conditions combined with monitoring of effects on the productivity of the animals • Collection of recent local field isolates

11

AN ENTREPRENEURIAL ORGANIZATION OF SCIENTISTS AND EXPERIENCED TECH TRANSFER PROFESSIONALS

WITH PROVAXS WE COMBINE • The insight and know how of professors and academic scientists who perform breakthrough research in their field of expertise.

• High quality management of the collaboration with our industrial partners by an experienced team of tech transfer professionals with special attention to swift contract negotiations, confidentiality of results and intellectual property and follow up of milestones and deliverables.

We are open for all kinds of collaboration with our partners: • PhD research with industrial applications: evaluate how results of early discovery projects can fit in your R&D-activities • R&D-collaboration: partner with our academic experts and research teams to validate your ideas or to complement your own R&Dcapacity • Outlicensing/co-development: accelerate your product development and build on validated research results, proof of concept data and intellectual property with a strong academic basis • Services: use our validated assays (in vitro, ex vivo, in situ) and animal models in your development program or post marketing studies

13

RESEARCH AND DEVELOPMENT

BACTERIOLOGY

Freddy Haesebrouck, Frank Pasmans, Filip Van Immerseel,

EXPERTISE

Daisy Vanrompay PARASITOLOGY

Edwin Claerebout, Peter Geldhof, Jozef Vercruysse

VIROLOGY

Herman Favoreel, Hans Nauwynck, Kristien Van Reeth

IMMUNOLOGY

Eric Cox

PATHOLOGY

Richard Ducatelle, Filip Van Immerseel

AUTO-IMMUNITY

Dirk Elewaut

FORMULATION

Dieter Deforce, Jo Demeester,

& DELIVERY

Stefaan De Smedt, Jean Paul Remon

14

BUSINESS DEVELOPMENT

MANAGEMENT

Sven Arnouts

& BUSINESS DEVELOPER ADMINISTRATIVE

Sarah Wambacq

ASSISTANT INTELLECTUAL

Nathalie Brutsaert

PROPERTY LEGAL

Bernadette Tuerlinckx

LICENSING

Piet De Vos

VC & CORPORATE

Patrick Dhaese

FINANCE FUNDING

Margo Baele (EU), Karen Curé (IWT), Ingrid Merchiers (IOF)

15

ACCESS TO PROOF OF CONCEPT FUNDING We have access to funding bodies like IWT (Flanders), FWO and the Federal Public Service Health Food Chain Safety and Environment (Belgium), Horizon2020 (EU).

Next to that Ghent University offers its researchers and their partners funding for exclusive use at crucial stages of the development track of innovation-oriented projects.

Depending on the stage of maturation three types of projects can be applied for.

STARTT • Identification/initiation • 75.000EURO • 1-2 year ADVANCED • Licence/spin-off or preparation of StepStone • 150.000EURO • Max 2 year • Cofinancing industrial partner is a strong asset STEPSTONE • Close to technology transfer • 500.000EURO • Max 3 year • Cofinancing industrial partner obligatory (license)

16

RESEARCH

Innovative research results

CONCEPT DEFINITION

TECHNICAL PROOF OF

IOF StarTT

CONCEPT

INDUSTRIAL PROOF OF CONCEPT

VALORISATION

IOF Advanced IOF Stepstone

License negotiations Spin-off incubation

These projects can thus be used to mature research results and novel technologies towards transfer to industrial partners or to create new start up companies: • Generate proof of concept data during the priority year of a patent application to support the claims • Generate additional data to validate a target or a technology and fill the gaps identified by an industrial partner interested in licensing • Evaluate industrial proof of concept and/or the market potential of a new technology in preparation of or as the first step of an academic-industrial partnership

17

THE GHENT INNOVATION HUB 18

At Ghent University we strongly believe that increased collaboration with our industrial partners can lead to cross-fostering and will increase innovation.

More than 6.000 researchers covering more than 80 nationalities are involved in basic research, working at the Ghent University Association, the Ghent University Hospital, or at one of the strategic research institutes like VIB (Flemish Institute for Biotechnology). In 2010, together they realized an R&D investment of more than 300 million euro, of which more than 30% was financed by industry, which illustrates the intensive collaboration with companies worldwide.

The city of Ghent houses the largest student population of Belgium with about 70.000 higher education students including more than 3.000 PhD students. Ghent University has 30.000 students, 10.000 of which are specializing in medicine and life sciences. The Ghent region is also an important economic hub within one hour drive from the capital of the European Union.

Ghent has three bio-incubators, currently housing 15 biotech/life science companies. In total some 40 biotech/life science companies are located in Ghent or the Ghent area, covering the health, industrial/ environmental and agricultural/food sectors.

19

FROM SERVICES TO NEW OPPORTUNITIES AND LEADS

Your collaboration with PROVAXS SERVICES will bring you into contact with our scientists, their expertise and the innovative ideas they are developing towards industrial applications.

Ghent University has created a number of business development centers that group complementary research departments by application and area or domain of expertise. Each center is responsible for technology transfer within its area of competence.

We can bring you into contact with these BD-centers and learn how the services that we offer at PROVAXS SERVICES can help to create further proof-of-concept to the innovations and technologies they offer.

21

Technology transfer at Ghent University wants to facilitate the commercial application of promising technologies developed within the Ghent University Association. Key technology transfer activities include industrial collaboration programs, IP licensing and spin-off creation. For its liaison with industry , UGent uses a network of specialized business development centres backed by a Central Technology Transfer Office.

CENTRAL TECHNOLOG energy

materials

electronics

& cleantech

& photonics

DuraBuildmaterials

22

ICT

GY TRANSFER OFFICE medical

pharma

biotech

23

food

CONTACT Sven Arnouts, PhD Business Developer PROVAXS - University of Ghent Salisburylaan 133, 9820 Merelbeke (BE) T +32 9 264 73 33 M +32 495 707 334 E sven.arnouts@ugent.be